Collaboration Costs. Each Party will be responsible for its own costs associated with performance of this Agreement, except as expressly set forth herein. It is anticipated that the financial benefits of the collaboration will be realized by each Party through sales of the Magnus Analyzer and increased demand for and sales of the NMR Subsystem and LipoScience Diagnostic Applications.
Collaboration Costs. Subject to Section 3.13(a)(vi), the Baker Hughes Entities and the GE Entities shall pay the fees, costs and expenses owed by such parties under any applicable Collaboration Agreements (such fees, costs and expenses, “Collaboration Costs”), in each case in accordance with and subject to the terms of such Collaboration Agreements.
Collaboration Costs. 7.Novartis shall be responsible for one hundred percent (100%) of its own costs incurred in performing the activities assigned to it under the applicable Collaboration Plan and, subject to this Section 4.4, one hundred percent (100%) of the Internal Costs (comprised of up to [*], plus, to the extent approved in advance by Novartis, any [*]) and Out-of-Pocket Costs incurred by Sangamo in performing the activities assigned to it under the applicable Collaboration Plan (comprised of the total Out-of-Pocket Costs set forth on Exhibit K ([*]), as [*] = Certain confidential information contained in this document, marked by brackets, has been omitted because it is both (i) not material and (ii) would be competitively harmful if publicly disclosed.Confidential Execution Versionsuch Out-of-Pocket Costs may be reallocated in accordance with Section 4.4(e); provided, that the total Out-of-Pocket Costs set forth on Exhibit K shall automatically be deemed to be updated to account for any amended Collaboration Budget approved by the JSC in accordance with Section 4.2 and confirmed in writing by the Parties) (such Internal Costs and Out-of-Pocket Costs, the “Collaboration Costs”); provided, that, prior to Sangamo having any obligation to incur Internal Costs or Out-of-Pocket Costs in excess of the Collaboration Costs as a result of (i) Novartis electing to extend the Collaboration Term pursuant to Section 4.1 or (ii) Novartis selecting a Replacement Target in accordance with Section 4.8, the Parties shall agree upon revised Collaboration Costs (including a revised number of FTEs over a revised period of time for Internal Costs) with respect to Sangamo’s performance of the activities assigned to it under the Collaboration Plan with respect to the extended Collaboration Term or the Replacement Target, as applicable.8.No later than [*] Business Days following the beginning of each Calendar Quarter, Sangamo shall provide to Novartis a good faith, non-binding estimate (in a form to be agreed by the Parties promptly following the Effective Date) of the Collaboration Costs it anticipates incurring during such Calendar Quarter under each Collaboration Plan.9.Within [*] days after the end of each Calendar Quarter during the performance of the Collaboration, Sangamo shall submit to Novartis an Invoice (accompanied by reasonable supporting documents) setting forth the Collaboration Costs incurred by Sangamo in such Calendar Quarter to perform activities assigned to it under a Colla...
Collaboration Costs. SymBio shall provide Eagle with all reasonable assistance and cooperation in Eagle’s patent prosecution efforts regarding the Eagle Licensed Patents under Section 9.2(a), and Eagle shall provide SymBio with all reasonable assistance and cooperation in SymBio’s patent prosecution efforts regarding the SymBio Collaboration Patents under Section 9.2(b), including in each case providing any necessary powers of attorney and executing any other required documents or instruments for such prosecution. Each Party shall bear [ * ] of all out-of-pocket costs incurred by the prosecuting Party in its patent prosecution efforts in the SymBio Territory under Section 9.2(a) and Section 9.2(b) and [ * ] incurred by the other Party in providing assistance and cooperation in such prosecution efforts in the SymBio Territory under this Section 9.2(c). Without limiting the foregoing, at Eagle’s request, SymBio shall provide consent, and shall execute documents reflecting such consent, to any changes or corrections in any claims of Eagle Licensed Patents that Eagle elects to make in connection with any invalidation (nullity) actions or other opposition proceedings brought by Third Parties against such Eagle Licensed Patents in the SymBio Territory.
Collaboration Costs. The estimated costs for Translate Bio’s Collaboration Activities will be as set forth in the applicable Collaboration Budget; provided, however, that Sanofi shall be responsible for paying FTE Costs, Out-of-Pocket Costs and Manufacturing Costs up to [**] percent ([**]%) of such costs set forth in the applicable Collaboration Budget with respect to the Translate Bio Collaboration Activities. Any variation in excess of [**] percent ([**]%) of the Collaboration Budget will require Sanofi’s express prior written consent.
Collaboration Costs. Unless otherwise agreed to by the Parties, Roche shall (i) pay 4DMT at the FTE Rate for work performed by or on behalf of 4DMT under a given Project Plan and (ii) reimburse 4DMT for the expenses of a Third Party Supplier (“Third Party Expenses”) that 4DMT incurred under a given Project Plan as set forth in Section 11.2. Notwithstanding the foregoing, [***]. The number of FTEs per month that may not be exceeded without mutual agreement of the Parties will be included in each corresponding Project Plan. If the Parties mutually agree to conduct work in under a Project Plan in areas of the Field other than the [***] (for example in a Field [***]), it is expected that costs under the Project Plan will be [***].